Relypsa Loads $80M Series C to Fund Patiromer Phase III
Relypsa Inc. moved patiromer (RLY5016), its high-capacity nonabsorbed oral potassium binder, closer to the finish line in hyperkalemia by closing an $80 million Series C preferred stock financing to fund pivotal Phase III trials and submission of a new drug application (NDA).
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST